Details

Autor(en) / Beteiligte

• Wang, Zhijie
• Wu, Lin
• Li, Baolan
• Cheng, Ying
• Li, Xiaoling
• Wang, Xicheng
• Han, Liang
• Wu, Xiaohong
• Fan, Yun
• Yu, Yan
• Lv, Dongqing
• Shi, Jianhua
• Huang, Jianjin
• Zhou, Shaozhang
• Han, Baohui
• Sun, Guogui
• Guo, Qisen
• Ji, Youxin
• Zhu, Xiaoli
• Hu, Sheng
• Zhang, Wei
• Wang, Qiming
• Jia, Yuming
• Wang, Ziping
• Song, Yong
• Wu, Jingxun
• Shi, Meiqi
• Li, Xingya
• Han, Zhigang
• Liu, Yunpeng
• Yu, Zhuang
• Liu, An-Wen
• Wang, Xiuwen
• Zhou, Caicun
• Zhong, Diansheng
• Miao, Liyun
• Zhang, Zhihong
• Zhao, Hui
• Yang, Jun
• Wang, Dong
• Wang, Yingyi
• Li, Qiang
• Zhang, Xiaodong
• Ji, Mei
• Yang, Zhenzhou
• Cui, Jiuwei
• Gao, Beili
• Wang, Buhai
• Liu, Hu
• Nie, Lei
• He, Mei
• Jin, Shi
• Gu, Wei
• Shu, Yongqian
• Zhou, Tong
• Feng, Jian
• Yang, Xinmei
• Huang, Cheng
• Zhu, Bo
• Yao, Yu
• Tang, Xiongwen
• Yu, Jianjun
• Maher, Ellen
• Feng, Hui
• Yao, Sheng
• Keegan, Patricia
• Wang, Jie

Titel

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Ist Teil von

• Journal of clinical oncology, 2023-01, Vol.41 (3), p.651-663

Ort / Verlag

United States: Wolters Kluwer Health

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). Patients (N = 465) with treatment-naive, advanced NSCLC without mutations were randomly assigned 2:1 to receive toripalimab 240 mg (n = 309) or placebo (n = 156) once every 3 weeks in combination with chemotherapy for 4-6 cycles, followed by the maintenance of toripalimab or placebo once every 3 weeks plus standard care. Stratification factors included programmed death ligand-1 expression status, histology, and smoking status. The primary end point was progression-free survival (PFS) by investigator per RECIST v1.1. Secondary end points included overall survival and safety. At the final PFS analysis, PFS was significantly longer in the toripalimab arm than in the placebo arm (median PFS, 8.4 5.6 months, hazard ratio = 0.49; 95% CI, 0.39 to 0.61; two-sided < .0001). At the interim OS analysis, the toripalimab arm had a significantly longer OS than the placebo arm (median OS not reached 17.1 months, hazard ratio = 0.69; 95% CI, 0.53 to 0.92; two-sided = .0099). The incidence of grade ≥ 3 adverse events was similar between the two arms. Treatment effects were similar regardless of programmed death ligand-1 status. Genomic analysis using whole-exome sequencing from 394 available tumor samples revealed that patients with high tumor mutational burden were associated with significantly better PFS in the toripalimab arm (median PFS 13.1 5.5 months, interaction = .026). Notably, patients with mutations in the focal adhesion-PI3K-Akt signaling pathway achieved significantly better PFS and OS in the toripalimab arm (interaction values ≤ .001). Toripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC while having a manageable safety profile. Subgroup analysis showed the OS benefit was mainly driven by the nonsquamous subpopulation.